SCHEMBL4277404

SCHEMBL4277404

CC(C)n1cnc2c(NCc3ccccc3)nc(N(CCO)Cc3ccccc3)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 10/20 1.00
CDK5 Q00535 5/20 1.00
CDK2 P24941 12/20 0.86
CCNE2 O96020 10/20 0.86
CCNE1 P24864 10/20 0.86
CCNB1 P14635 5/20 0.72
CCNT1 O60563 1/20 0.72
PDE5A O76074 1/20 0.72
CCNA2 P20248 1/20 0.72
CDK7 P50613 1/20 0.72
CDK9 P50750 1/20 0.72
CCNH P51946 1/20 0.72
MNAT1 P51948 1/20 0.72
PDE4D Q08499 1/20 0.72
CDK5R1 Q15078 1/20 0.72
PDE10A Q9Y233 1/20 0.72
CSNK1D P48730 1/20 0.64
CLK2 P49760 1/20 0.64
DYRK1A Q13627 1/20 0.64
HIPK4 Q8NE63 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2364042 0.93 CDK1 (0.87) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL14071580 0.87 CDK2 (0.85) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL3332989 0.86 CDK1 (0.76) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL6143053 0.85 CDK2 (1.00) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL3680752 0.85 CCNE1 (0.82) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL1394958 0.83 CCNE2 (1.00) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL5827556 0.83 CCNE2 (0.78) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL5828748 0.81 CCNE1 (0.75) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL7098593 0.81 KDM4E (0.70) CDK1CDK5CDK2CCNE2CCNE1
SCHEMBL17450143 0.80 CDK1 (0.66) CDK1CDK5CDK2CCNE2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030019-A1 PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2009-01-29 US claimed
US-20030186999-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2003-10-02 US claimed
EP-1308447-A1 Purine derivatives having antiproliferative properties and biological uses thereof Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2003-05-07 EP claimed
US-20020049218-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2002-04-25 US claimed
EP-0874847-A1 NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1998-11-04 EP claimed
WO-1997020842-A1 NOVEL PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTIPROLIFERATIVE PROPERTIES, AND BIOLOGICAL USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 1997-06-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186999-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses PNP, TYMP, NUDT1 CDK1 501/4885CDK5 517/4885CDK2 359/4885
US-20020049218-A1 Purine derivatives having, in particular, antiproliferative properties, and their biological uses PNP, TYMP, NUDT1 CDK1 501/4885CDK5 517/4885CDK2 359/4885
US-20090030019-A1 PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES PNP, TYMP, NUDT1 CDK1 516/4885CDK5 464/4885CDK2 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.